Drug Profile
T 101
Alternative Names: Hepatitis B adenovirus injection; T101Latest Information Update: 26 Jul 2022
Price :
$50
*
At a glance
- Originator Transgene - Tasly Pharmaceutics Group (JV)
- Class Antivirals; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 26 Jul 2022 T 101 is still in phase II trials in Hepatitis B (Combination therapy) in China (SC) (NCT04189276)
- 10 Dec 2019 Phase-II clinical trials in Hepatitis B (Combination therapy) in China (SC) (NCT04189276)
- 06 Dec 2019 Tasly Tianjin Biopharmaceutical plans a phase II trial for Hepatitis B virus (HBV) (Combination therapy) in December 2019 (SC) (NCT04189276)